Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SBFM
stocks logo

SBFM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
11.20M
+20.39%
--
--
11.10M
+31.59%
--
--
12.00M
+25.07%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Sunshine Biopharma, Inc. (SBFM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.27%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+6.27%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Sunshine Biopharma Inc (SBFM.O) is -2.92, compared to its 5-year average forward P/E of -1.56. For a more detailed relative valuation and DCF analysis to assess Sunshine Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.56
Current PE
-2.92
Overvalued PE
0.76
Undervalued PE
-3.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.14
Current PS
0.00
Overvalued PS
0.37
Undervalued PS
-0.09
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 11812.88% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SBFM News & Events

Events Timeline

(ET)
2025-10-28
07:48:02
Nora Pharma, a subsidiary of Sunshine Biopharma, gets Health Canada approval for domperidone.
select
2025-10-20 (ET)
2025-10-20
07:47:05
Sunshine Biopharma Reveals Launch of Doxycycline for Sale in Canada
select
2025-10-16 (ET)
2025-10-16
07:49:20
Nora Pharma, a subsidiary of Sunshine Biopharma, introduces pravastatin.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
10-09Benzinga
Aegis Capital Affirms Buy Rating for Sunshine Biopharma, Keeps $7 Price Target Intact
  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights from Benzinga reporters.
[object Object]
Preview
2.0
04-03TipRanks
3 Penny Stocks to Watch Now, 4/3/25

  • Penny Stocks to Watch: Sportsman’s Warehouse, Sunshine Biopharma, and ConnectM Technology Solutions are highlighted as top penny stocks on April 3, 2025, based on their high Dollar Volume and significant stock price movements following positive company news.

  • Company Highlights: Sportsman’s Warehouse saw a nearly 98% increase in stock price after strong Q4 results; Sunshine Biopharma reported a 45% revenue increase and positive study results; ConnectM Technology's shares surged due to a buyout proposal amid delisting concerns.

[object Object]
Preview
9.0
04-02Benzinga
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

  • Stock Performance: Sunshine Biopharma Inc. (SBFM) saw a significant increase in stock price, rising 69.2% to $3.52, with trading volume reaching 19.07 million shares on Wednesday, compared to an average of 88.16K.

  • Research Advancements: The company announced successful studies on its K1.1 mRNA Lipid Nanoparticle product for treating human hepatocellular carcinoma, demonstrating effective tumor growth reduction and promising results for both full-length and truncated mRNA versions in mouse models.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sunshine Biopharma Inc (SBFM) stock price today?

The current price of SBFM is 1.44 USD — it has decreased -1.37 % in the last trading day.

arrow icon

What is Sunshine Biopharma Inc (SBFM)'s business?

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

arrow icon

What is the price predicton of SBFM Stock?

Wall Street analysts forecast SBFM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBFM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sunshine Biopharma Inc (SBFM)'s revenue for the last quarter?

Sunshine Biopharma Inc revenue for the last quarter amounts to 9.42M USD, increased 11.64 % YoY.

arrow icon

What is Sunshine Biopharma Inc (SBFM)'s earnings per share (EPS) for the last quarter?

Sunshine Biopharma Inc. EPS for the last quarter amounts to -0.19 USD, decreased -79.79 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sunshine Biopharma Inc (SBFM)'s fundamentals?

The market is revising No Change the revenue expectations for Sunshine Biopharma, Inc. (SBFM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.27%.
arrow icon

How many employees does Sunshine Biopharma Inc (SBFM). have?

Sunshine Biopharma Inc (SBFM) has 52 emplpoyees as of December 05 2025.

arrow icon

What is Sunshine Biopharma Inc (SBFM) market cap?

Today SBFM has the market capitalization of 7.06M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free